Stocks and Investing
Stocks and Investing
Thu, July 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, July 17, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tommie Reerink Maintained (ATRA) at Strong Sell with Decreased Target to $11 on, Jul 17th, 2024
Tommie Reerink of Goldman Sachs, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Strong Sell with Decreased Target from $13 to $11 on, Jul 17th, 2024.
Tommie has made no other calls on ATRA in the last 4 months.
There are 2 other peers that have a rating on ATRA. Out of the 2 peers that are also analyzing ATRA, all agree with Tommie's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Robert Burns of "HC Wainwright & Co." Reiterated at Hold on, Wednesday, May 22nd, 2024
- Benjamin Burnett of "Stifel" Maintained at Hold with Decreased Target to $58 on, Monday, April 1st, 2024
Contributing Sources